Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) subsidiary Xingsheng Xinhui Pharmaceutical received approval from China's medical products administrator to conduct clinical trials for a colorectal cancer drug.
Specifically, the approval was for trials using XS-03 tablets in combination with FOLFOX or FOLFIRI and bevacizumab for the treating RAS-mutated metastatic colorectal cancer, according to a Thursday filing with the Shanghai bourse.
Xingsheng Xinhui plans to initiate Phase Ib/II clinical trials for this treatment regimen in mainland China once conditions are met.
Shares of the pharmaceutical company were down 1% in recent trade on the Shanghai bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.